Lyell Immunopharma, Inc. Basic Shares Outstanding (Weighted Average)
Lyell Immunopharma, Inc. (LYEL) reported Basic Shares Outstanding (Weighted Average) of 23.36 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 23.36M shares, a 57.94% increase year-over-year.
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 21.88M shares, a 48.26% increase year-over-year.
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 20.52M shares, a 46.56% increase year-over-year.
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 18.27M shares, a 42.55% increase year-over-year.
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 17.09M shares, a 30.74% increase from fiscal 2024.
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 13.07M shares, a 4.18% increase from fiscal 2023.
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 12.55M shares, a 94.92% decline from fiscal 2022.
- Lyell Immunopharma, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 247.08M shares, a 81.79% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 23.36M shares 10-Q · filed 2026-08-06 | 22.62M shares 10-Q · filed 2026-08-06 | 21.92M shares derived: average of 3 quarters · filed 2026-08-06 | 21.01M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | 21.88M shares 10-Q · filed 2026-05-06 | 21.20M shares derived: average of 2 quarters · filed 2026-05-06 | 20.22M shares derived: average of 3 quarters · filed 2026-05-06 | 18.86M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | 20.52M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 19.39M shares derived: average of 2 quarters · filed 2026-03-12 | 17.86M shares derived: average of 3 quarters · filed 2026-08-06 | 17.09M shares 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | 18.27M shares 10-Q · filed 2025-11-12 | 16.53M shares derived: average of 2 quarters · filed 2026-08-06 | 15.95M shares 10-Q · filed 2025-11-12 | 15.45M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | 14.79M shares 10-Q · filed 2026-08-06 | 14.77M shares 10-Q · filed 2026-08-06 | 14.52M shares derived: average of 3 quarters · filed 2026-08-06 | 14.09M shares derived: average of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | 14.76M shares 10-Q · filed 2026-05-06 | 295.10M shares 10-Q · filed 2025-05-13 | 14.38M shares derived: average of 2 quarters · filed 2026-05-06 | 13.86M shares derived: average of 3 quarters · filed 2026-05-06 | 13.58M shares derived: average of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | 14.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 13.41M shares derived: average of 2 quarters · filed 2026-03-12 | 13.19M shares derived: average of 3 quarters · filed 2026-03-12 | 13.07M shares 10-K · filed 2026-03-12 | 261.48M shares 10-K · filed 2025-03-11 | |||
| 2024-09-30 | 12.81M shares 10-Q · filed 2025-11-12 | 256.31M shares 10-Q · filed 2024-11-07 | 12.79M shares derived: average of 2 quarters · filed 2025-11-12 | 12.77M shares 10-Q · filed 2025-11-12 | 255.32M shares 10-Q · filed 2024-11-07 | -105.27M shares derived: average of 4 quarters · filed 2026-03-12 | ||
| 2024-06-30 | 12.77M shares 10-Q · filed 2025-08-12 | 255.40M shares 10-Q · filed 2024-08-07 | 12.74M shares 10-Q · filed 2025-08-12 | 254.82M shares 10-Q · filed 2024-08-07 | -144.64M shares derived: average of 3 quarters · filed 2026-03-12 | -45.65M shares derived: average of 4 quarters · filed 2026-03-12 | ||
| 2024-03-31 | 254.25M shares 10-Q · filed 2025-05-13 | -223.34M shares derived: average of 2 quarters · filed 2026-03-12 | -65.12M shares derived: average of 3 quarters · filed 2026-03-12 | 13.71M shares derived: average of 4 quarters · filed 2026-03-12 | ||||
| 2023-12-31 | -700.93M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -224.81M shares derived: average of 2 quarters · filed 2026-03-12 | -66.47M shares derived: average of 3 quarters · filed 2026-03-12 | 12.55M shares 10-K · filed 2026-03-12 | 250.98M shares 10-K · filed 2024-02-28 | |||
| 2023-09-30 | 251.32M shares 10-Q · filed 2024-11-07 | 250.76M shares derived: average of 2 quarters · filed 2024-11-07 | 250.38M shares 10-Q · filed 2024-11-07 | 250.14M shares derived: average of 4 quarters · filed 2025-03-11 | ||||
| 2023-06-30 | 250.20M shares 10-Q · filed 2024-08-07 | 249.90M shares 10-Q · filed 2024-08-07 | 249.75M shares derived: average of 3 quarters · filed 2025-03-11 | 249.40M shares derived: average of 4 quarters · filed 2025-03-11 | ||||
| 2023-03-31 | 249.59M shares 10-Q · filed 2024-05-06 | 249.53M shares derived: average of 2 quarters · filed 2025-03-11 | 249.13M shares derived: average of 3 quarters · filed 2025-03-11 | 248.42M shares derived: average of 4 quarters · filed 2025-03-11 | ||||
| 2022-12-31 | 249.47M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 248.89M shares derived: average of 2 quarters · filed 2025-03-11 | 248.03M shares derived: average of 3 quarters · filed 2025-03-11 | 247.08M shares 10-K · filed 2025-03-11 | ||||
| 2022-09-30 | 248.32M shares 10-Q · filed 2023-11-07 | 247.32M shares derived: average of 2 quarters · filed 2023-11-07 | 246.28M shares 10-Q · filed 2023-11-07 | 245.17M shares derived: average of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | 246.31M shares 10-Q · filed 2023-08-08 | 245.25M shares 10-Q · filed 2023-08-08 | 244.12M shares derived: average of 3 quarters · filed 2024-02-28 | 242.93M shares derived: average of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | 244.18M shares 10-Q · filed 2023-05-04 | 243.02M shares derived: average of 2 quarters · filed 2024-02-28 | 241.81M shares derived: average of 3 quarters · filed 2024-02-28 | 192.03M shares derived: average of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | 241.86M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 240.62M shares derived: average of 2 quarters · filed 2024-02-28 | 174.65M shares derived: average of 3 quarters · filed 2024-02-28 | 135.92M shares 10-K · filed 2024-02-28 | 135.92K shares 10-K · filed 2022-03-29 | |||
| 2021-09-30 | 239.38M shares 10-Q · filed 2022-11-08 | 141.05M shares derived: average of 2 quarters · filed 2022-11-08 | 100.60M shares 10-Q · filed 2022-11-08 | |||||
| 2021-06-30 | 42.71M shares 10-Q · filed 2022-08-04 | 30.06M shares 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | 17.27M shares 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | 13.26M shares 10-K · filed 2023-02-28 | 13.26K shares 10-K · filed 2022-03-29 | ||||||
| 2019-12-31 | 5.43K shares 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |